Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1

Status

Unknown 3Recruiting 2Not yet recruiting 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 1401Neoplasms 1128Prostatic Neoplasms 745Lung Neoplasms 621Colorectal Neoplasms 599Carcinoma, Non-Small-Cell Lung 570Carcinoma, Hepatocellular 414Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 398Stomach Neoplasms 356Multiple Myeloma 326Brain Neoplasms 311Ovarian Neoplasms 310Head and Neck Neoplasms 290Neoplasm Metastasis 275Precursor Cell Lymphoblastic Leukemia-Lymphoma 260Rectal Neoplasms 254Uterine Cervical Neoplasms 248Recurrence 248Melanoma 243Esophageal Neoplasms 237Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Lymphoma 214Sarcoma 209Urinary Bladder Neoplasms 192Colonic Neoplasms 192Glioma 191Triple Negative Breast Neoplasms 188Hematologic Neoplasms 182

Interventions

mirabegron 1liposomal doxorubicin 1disitamab vedotin 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × OTHER × Ovarian Cancer Recurrent × Clear all
NCT06791460 2025-03-18

Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer

Obstetrics & Gynecology Hospital of Fudan University

Phase 2/3 Recruiting
296 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT06660511 2024-10-28

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Second Xiangya Hospital of Central South University

Phase EARLY_PHASE1 Recruiting
5 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡